Marker Therapeutics Inc (MRKR) - Total Liabilities
Based on the latest financial reports, Marker Therapeutics Inc (MRKR) has total liabilities worth $3.35 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Marker Therapeutics Inc cash conversion from operations to assess how effectively this company generates cash.
Marker Therapeutics Inc - Total Liabilities Trend (1999–2024)
This chart illustrates how Marker Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See Marker Therapeutics Inc (MRKR) net assets for net asset value and shareholders' equity analysis.
Marker Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Marker Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Salee Colour Public Company Limited
BK:COLOR
|
Thailand | ฿515.70 Million |
|
Vereinigte Filzfabriken AG
MU:VFF
|
Germany | €6.57 Million |
|
UMS Holdings Bhd
KLSE:7137
|
Malaysia | RM8.35 Million |
|
Aurora Labs Ltd
AU:A3D
|
Australia | AU$1.84 Million |
|
Agung Semesta Sejahtera Tbk PT
JK:TARA
|
Indonesia | Rp18.99 Billion |
|
Tandy Leather Factory Inc
NASDAQ:TLF
|
USA | $31.16 Million |
|
Muar Ban Lee Group Bhd
KLSE:5152
|
Malaysia | RM95.58 Million |
Liability Composition Analysis (1999–2024)
This chart breaks down Marker Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see MRKR market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.50 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Marker Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Marker Therapeutics Inc (1999–2024)
The table below shows the annual total liabilities of Marker Therapeutics Inc from 1999 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $3.46 Million | +12.67% |
| 2023-12-31 | $3.07 Million | -79.25% |
| 2022-12-31 | $14.82 Million | -38.63% |
| 2021-12-31 | $24.15 Million | +32.18% |
| 2020-12-31 | $18.27 Million | +703.77% |
| 2019-12-31 | $2.27 Million | -18.92% |
| 2018-12-31 | $2.80 Million | +84.17% |
| 2017-12-31 | $1.52 Million | -12.35% |
| 2016-12-31 | $1.74 Million | -93.80% |
| 2015-12-31 | $28.01 Million | +2143.90% |
| 2014-12-31 | $1.25 Million | -85.89% |
| 2013-12-31 | $8.85 Million | +53.27% |
| 2012-12-31 | $5.77 Million | +51.84% |
| 2011-12-31 | $3.80 Million | +12.15% |
| 2010-12-31 | $3.39 Million | +243.58% |
| 2009-12-31 | $986.35K | -67.94% |
| 2008-12-31 | $3.08 Million | +57.44% |
| 2007-12-31 | $1.95 Million | -38.06% |
| 2006-12-31 | $3.15 Million | +36.58% |
| 2005-12-31 | $2.31 Million | -8.65% |
| 2004-12-31 | $2.53 Million | +243.08% |
| 2003-12-31 | $736.95K | +149.31% |
| 2002-12-31 | $295.60K | +70.84% |
| 2001-12-31 | $173.03K | -74.66% |
| 2000-12-31 | $682.74K | +135.66% |
| 1999-12-31 | $289.71K | -- |
About Marker Therapeutics Inc
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-assoc… Read more